The biggest story today is earnings. Alphabet reports after the close, with investors watching closely for AI revenue data. It is a $2 trillion company under real scrutiny. IBM, Texas Instruments, and AT&T also post results today. Tomorrow brings Intel, which has delivered roughly 7x returns since its Dow addition — analysts want to know if that run has legs. RTX reports Wednesday morning too, with tariff cost clarity the key question. This is one of the busiest earnings weeks of the year.
Tesla Q2 results are out. Deliveries jumped, but the real question is whether profit followed. Options flow has been mixed — bulls and bears both active. Short interest remains elevated, and the earnings print will set the tone for the rest of the week.
The semiconductor sector is divided. Intel heads into earnings on a strong run. Meanwhile, bears are pushing back on memory names. Sandisk drew the largest block of bearish options bets this week. Micron ranked second. Both stocks have tripled or more in 2026. On the bullish side, MaxLinear saw 95% of its options flow skew positive ahead of its own earnings.
GSK won FDA approval today for Jideytro to treat ROS1-positive non-small cell lung cancer. The approval covers previously treated patients. It is a fresh catalyst for the UK pharma giant and adds to a busy day across both sides of the Atlantic.
Palantir is falling today despite no obvious fundamental shift — analysts are watching valuation closely. GE Vernova and Interactive Brokers both saw target price increases from analysts this week, reflecting growing confidence in energy transition and brokerage earnings momentum.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
